Clinical Trials Logo

Clinical Trial Summary

Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approximately 7000 children aged <21 years who are receiving these drugs for standard of care will be enrolled and will be followed for up a maximum of 90 days. The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws) this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care. The data collected through this initiative will also provide valuable pharmacokinetic and dosing information of drugs in different pediatric age groups as well as special pediatric populations (i.e. obese).


Clinical Trial Description

The purpose of this study is to characterize the PK ( Pharmacokinetics) of understudied drugs administered to children per standard of care as prescribed by their treating caregiver. This will be accomplished by the collection of biological samples during the time of drug administration per standard of care as prescribed by the caregiver. The prescribing of drugs to children will not be part of this protocol. Aim #1: Evaluate the PK of understudied drugs currently being administered to children. Hypothesis #1: The PK of understudied drugs in children will differ from adults and within children according to pediatric age groups or special population. Aim #2: Explore the pharmacodynamics (PD) of understudied drugs currently being administered to children. Hypothesis #2: The PD of targeted drugs in children will differ from adults. Aim #3: Evaluate the influence of genetic factors, metabolic and protein profiles on therapeutic exposure. Hypothesis #3: Genetic polymorphisms in drug metabolizing enzymes and metabolic and proteomic profiles will impact drug exposure in children. ;


Study Design


Related Conditions & MeSH terms

  • Adenoviridae Infections
  • Adenovirus
  • Anesthesia
  • Anxiety
  • Anxiolysis
  • Arrhythmias, Cardiac
  • Autism
  • Autistic Disorder
  • Bacterial Meningitis
  • Bacterial Septicemia
  • Benzodiazepine
  • Bipolar Disorder
  • Bone and Joint Infections
  • Bradycardia
  • Cardiac Arrest
  • Cardiac Arrhythmia
  • Central Nervous System Infections
  • Chronic Kidney Diseases
  • CMV Retinitis
  • Communicable Diseases
  • Convulsions
  • Cytomegalovirus Retinitis
  • Early-onset Schizophrenia Spectrum Disorders
  • Endocarditis
  • Epilepsy
  • Fibrinolytic Bleeding
  • General Anesthesia
  • Gram-negative Infection
  • Gynecologic Infections
  • Headache
  • Healthcare-Associated Pneumonia
  • Heart Failure
  • Heavy Menstrual Bleeding
  • Hemangioma
  • Hemangioma, Capillary
  • Hemophilia
  • Hemophilia A
  • Hemorrhage
  • Herpes Simplex
  • Herpes Simplex Virus
  • Hyperaldosteronism
  • Hyperkinesis
  • Hypertension
  • Hypokalemia
  • Infantile Hemangioma
  • Infection
  • Infections
  • Inflammation
  • Inflammatory Conditions
  • Insomnia
  • Intra-abdominal Infections
  • Intraabdominal Infections
  • Kidney Diseases
  • Lower Respiratory Tract Infections
  • Meningitis
  • Meningitis, Bacterial
  • Menorrhagia
  • Methicillin Resistant Staphylococcus Aureus
  • Migraines
  • Muscle Cramp
  • Neuromuscular Blockade
  • Neutropenia
  • Nosocomial Pneumonia
  • Pain
  • Pneumonia
  • Port-Wine Stain
  • Pulmonary Arterial Hypertension
  • Renal Insufficiency, Chronic
  • Respiratory Tract Infections
  • Retinitis
  • Schizophrenia
  • Sedation
  • Seizures
  • Sepsis
  • Skeletal Muscle Spasms
  • Skin and Skin-structure Infections
  • Spasm
  • Staphylococcal Infections
  • Toxemia
  • Treatment-resistant Schizophrenia
  • Urinary Tract Infections
  • Withdrawal

NCT number NCT01431326
Study type Observational
Source Duke University
Contact
Status Completed
Phase
Start date November 2011
Completion date November 2019

See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A